Genome-wide analysis of human cancers has shown that p53 mutations are tightly associated with the loss of RP expression or activity, particularly ribosomal protein L5 (RPL5) and L11 (RPL11) mutations, which have recently reinforced the link between ribosomal defects and cancer in multiple tumor types (Figure 2) [44]. The gene discussed is RPL11; the disease is neoplasm.